Pancreatic Cancer Treatment Market Size, Share & Industry Analysis, By Type (Exocrine and Endocrine), By Treatment Type (Chemotherapy, Radiation Therapy, and Others), By End-user (Hospitals, Clinics, and Others), and Regional Forecast, 2024-2032

The global pancreatic cancer treatment market size was valued at USD 2.86 billion in 2023. The market is projected to grow from USD 3.30 billion in 2024 to USD 10.69 billion by 2032, exhibiting a CAGR of 15.8% during the forecast period. Moreover, the U.S. pancreatic cancer treatment market size is projected to grow significantly, reaching an estimated value of USD 5.25 billion by 2032, driven by the presence of advanced healthcare facilities and the adoption of new technologies used in diagnosis.

Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment.

• For instance, according to an article published by GLOBOCAN, approximately 56,654 new cases of pancreatic cancer were reported in 2020 in the U.S. Moreover, 47,683 deaths occurred owing to cancer in the United Sates.


• According to an article published by Macmillan Cancer Support U.K., around 10,500 new cases of pancreatic cancer were diagnosed in the U.K. in 2019.

Moreover, the prevalence is significantly higher in the geriatric population compared to other types of cancers. Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth. The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers. The increase in the number of patients suffering from the condition has increased the demand for the drugs used in treatment. These are some factors driving the growth during the forecast period.

Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment. Additionally, the companies operating in the market have received approval from several regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others, thereby propelling the growth of the market. Moreover, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer. The increase in the diagnosis rates is driving the demand for drugs, thereby providing opportunities for the players.

• For instance, in December 2019, the U.S. Food and Drug Administration (FDA) approved the use of olaparib to treat patients suffering from metastatic pancreatic cancer.

The number of patient visits for cancer screening declined during the pandemic owing to the presence of limited personnel performing these procedures. Moreover, the governments of several countries introduced new regulations, thereby leading to a decline in surgical and diagnostic procedures to reduce the spread of COVID-19. This led to a decline in the sale of the drugs used for pancreatic type of cancer treatment.

• For instance, Sutent, a drug used for pancreatic cancer treatment, generated a revenue of USD 819.0 million in 2020 and witnessed a decline of 13.0% compared to USD 936.0 million in 2019.

However, the revoking lockdown restrictions, introduction of products by the key players in the market, and re-establishment of the supply chain networks increased the demand for drugs for the treatment of cancer in 2021. The market is henceforth projected to grow at a robust CAGR over the forecast period of 2024-2032.

Pancreatic Cancer Treatment Market Trends

Presence of Potential Pipeline Products to Drive the Market Growth

Shifting the focus of key players in extensive R&D activities to develop new drugs and an increase in funding for cancer research led to the development of new drugs for treatment. Additionally, several pharmaceutical companies are involved in clinical trials to develop new drugs and explore the potential of the molecule to treat the disease.

• For instance, in March 2019, Clovis Oncology published the data from the Rubraca (rucaparib) Phase 2 study in advanced pancreatic cancer, demonstrating the safety and efficacy of (rucaparib) in platinum-sensitive patients.


• Moreover, in August 2021, Aravive Inc. dosed the first patient in the Phase Ib portion of its Phase Ib/II trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced pancreatic adenocarcinoma. The Phase Ib portion of the clinical trial will analyze the tolerability, safety, pharmacodynamics, and pharmacokinetics of AVB-500 in combination with gemcitabine and nab-paclitaxel.

Similarly, the scientists from different research institutes are focusing more toward the development of personalized medicines for the treatment of pancreatic cancer.

• For instance, as per data provided by the National Institutes of Health in May 2023, a NIH-funded research team conducted a study for the development of personalized therapy for pancreatic cancers. Study findings demonstrated that the personalized mRNA vaccine elicited a strong immune response against pancreatic cancer in 50% of the participants.

Thus, with the increased funding for R&D activities, companies are focused on developing new drugs, thereby contributing to the overall rise in demand for drugs for pancreatic type of cancer treatment.

Request a Free sample to learn more about this report.

Pancreatic Cancer Treatment Market Growth Factors

Increasing Prevalence of Pancreatic Cancer to Augment Market Growth

The prevalence has increased significantly in the past few years, leading to an increase in the adoption of several treatment options.

• For instance, according to GlOBOCAN, around 14,461 new cases of pancreatic cancer were detected in France in 2020. The rate of incidences of new cases of this cancer was 7.9 per 100,000 men and 4.6 per 100,000 women in France.


• According to an article published by NCBI, around 21,859 new cases of pancreatic cancer were reported in Germany in 2021. The increase in cigarette smoking and the rise in tobacco consumption are some of the factors leading to the increase in cases of this cancer.

The increasing incidence among the population, coupled with government initiatives, is expected to propel the adoption of pancreatic cancer treatment drugs.

• For instance, according to a study published by the Korean Cancer Association in 2019, in Korea, cancer screening is provided to all people over 50 at no or minimal cost by the National Cancer Screening Program. The increasing aging population and government initiatives are expected to propel the adoption of screening tests, thereby presenting a large patient pool requiring treatment.

Furthermore, the increasing regulatory approvals of novel targeted therapies for treating pancreatic cancer have spurred the market growth. Additionally, the launches of immunotherapies in combination with chemotherapies showed promising survival rates for pancreatic cancer, further driving market growth.

• For instance, in January 2024, the U.S. FDA approved an investigational new drug application for ACT-IOP-003, an implantable iontophoretic product intended as a potential treatment for individuals diagnosed with pancreatic cancer. A phase 1b trial of this agent is scheduled to commence in mid-2024.

Thus, increasing aging population, supportive government policies, funding allocated for research and efforts to raise awareness about pancreatic cancer drive the market growth by encouraging research and development activities.

RESTRAINING FACTORS

High Cost and Side Effects Associated with Treatment Likely to Hinder Market Growth

The constant focus of market players on introducing new drugs has resulted in an increase in the cost of pancreatic cancer treatment. This has led to a shift in patient preference toward alternative treatment options, such as herbal therapy, which costs less than regular treatment.

• For instance, as per an article published by Cancers in March 2023, the systemic cost for pancreatic cancer is reported as the highest at USD 2.55 billion, with an average monthly cost of USD 3,156 per patient.


• Similarly, according to the American Society of Clinical Oncology, a six-month course of chemotherapy (Gemcitabine) costs around USD 23,500. With the combination of the drug Erlotinib, the treatment costs reach around USD 40,000.

This along with side effects associated with chemotherapy drugs such as pain, fever, dizziness, vomiting, and frequent bloody bowel movements are limiting their adoption. Additionally, shortness of breath, diarrhea, urinary and bladder problems, and changes in taste are some of the side effects associated with radiation therapy, which are likely to hamper the market growth.

Thus, the high cost associated with treatment and adverse reactions associated with chemotherapy and radiation therapy is expected to limit the market growth in the forecast period.

Pancreatic Cancer Treatment Market Segmentation Analysis

By Type Analysis

Increasing Adoption of Advanced Technologies for Diagnosis to Drive the Market Growth

Based on type, the market is classified into exocrine and endocrine.

The exocrine segment captured the largest market share in 2023. Exocrine cancer is more prevalent among patients. The majority of the pancreas is composed of exocrine cells forming the exocrine glands and ducts. The cancer cell development in the pancreas's ducts affects the pancreas's exocrine part. Cancer cell development occurs less in the endocrine part of the pancreas. Thus, owing to these factors, the diagnosis and the prevalence of exocrine pancreatic cancer are significantly high.

• For instance, according to an article published by the European Society for Medical Oncology, approximately 95% of diagnosed cancers are exocrine.

The increase in adoption of advanced technologies and increasing awareness among consumers regarding pancreatic endocrine tumors among the population are driving the growth of the segment.

Moreover, the increase in adoption of new technologies has led to an increase in the diagnosis of pancreatic endocrine cancer. Moreover, pancreatic endocrine tumors are more prevalent in the geriatric population. Thus, the increase in geriatric population, coupled with the increase in number of patients suffering from pancreatic neuroendocrine tumors, is expected to drive the growth of the segment.

• For instance, according to the American Cancer Society, approximately 4,300 people in the U.S. were diagnosed with pancreatic neuroendocrine tumors in 2022.

To know how our report can help streamline your business, Speak to Analyst

By Treatment Type Analysis

Increasing Adoption of Chemotherapy Drugs is expected to drive the Market Growth

Based on treatment type, the market has been segmented into chemotherapy, radiation therapy, and others.

The chemotherapy segment constituted the largest market share in 2023. Chemotherapy is used as the first line of treatment. Many patients suffering from this cancer receive chemotherapy, which provides long-term cancer protection. It eliminates the rapidly dividing abnormal cells and involves the application of chemicals and lasers to eradicate all diseased cells.  

• For instance, according to a report published by Lancet Oncology, around 9.8 million cancer patients worldwide received chemotherapy in 2018, and approximately 15 million cancer patients across the globe are anticipated to receive chemotherapy by 2040

The radiation therapy segment is expected to grow during the forecast period. An increase in the adoption of advanced technologies across hospitals and clinics to treat cancer patients has led to the adoption of advanced radiation therapy equipment.

• For instance, in August 2022, India’s Apollo Proton Cancer Centre (APCC) inked an agreement with Ion Beam Applications (IBA), Belgium, to provide proton-based radiation therapy training for clinicians.


• For instance, in August 2021, Manipal Hospitals, India’s second-largest multi-specialty hospital, launched an advanced Radixact System that comes with Synchrony Automatic, Real-time Motion Synchronization Technology for the precise treatment of cancer patients.

Thus, owing to these factors, the demand for radiation therapy is anticipated to rise in the coming years.

By End-user Analysis

Shifting Consumer Preference toward Hospitals to Propel the Segment Growth

Based on end-user, the market is classified into hospitals, clinics, and others.

Hospitals segment captured the largest market share in 2023. The majority of the patients receive primary care at hospitals. The segment's growth is primarily attributed to the increase in number of patients taking chemotherapy, radiation therapy, and other treatments at hospitals. The adoption of new technologies by hospitals for the diagnosis and treatment of this condition is expected to drive the growth of the segment.

The clinics segment accounted for a significant market share in the global market. The increase in the number of cancer patients visiting clinics for treatment is propelling the growth of the segment.

• For instance, according to the Centre for Disease Control and Prevention (CDC), around 650,000 cancer patients across the U.S. received treatment at outpatient clinics in the U.S. in 2020.

Thus, an increase in the number of clinics providing radiation therapy and chemotherapy and an increase in the privatization for the establishment of clinics contribute to expanding the clinic’s segment.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market in North America was valued at USD 1.35 billion in 2023. The presence of advanced healthcare facilities and the adoption of new technologies used in diagnosis constitute the growth of the market in the region. Additionally, the increase in prevalence of the condition across the U.S., presence of established players in the region, and increasing regulatory approvals are some of the factors propelling the growth of the pancreatic market in the region.

• For instance, Ipsen announced that the U.S. FDA had given approval for a supplemental new drug application for Onivyde in combination with oxaliplatin, fluorouracil, and leucovorin as a first-line treatment in adults with metastatic pancreatic adenocarcinoma.


• According to an article published by the National Institutes of Health (NIH), around 89,248 people in the U.S. in 2021 were living with pancreatic cancer. The rate of the incidences of new cases of this cancer was 13.3 per 100,000 men and women per year.

Europe held the second-largest pancreatic cancer treatment market share. The prevalence of the condition is significantly high across Germany, France, Italy, and Spain. The growth in the region is attributed to the increase in R&D investment by major players, favorable government regulations, and the launch of awareness programs by the government are some of the factors propelling the market growth in the region.

• For instance, in 2021, Servier Hellas Pharmaceutique Ltd organized a program at the French Embassy to increase awareness of pancreatic cancer across France.

Asia Pacific is anticipated to expand at the highest CAGR during the forecast period. The rising prevalence, improvement in healthcare infrastructure, and increase in the number of pharmaceutical companies developing products for pancreatic cancer treatment are some of the factors propelling the growth of the region.

• According to the Janssen Asia Pacific, Asia Pacific hosts 50% of the world’s new cancer cases each year, and deaths caused by cancer in Asia are expected to increase by 36.0% by 2030. Asia Pacific is expected to be one of the hotspots for cancer. The increase in new cancer cases across the region increases the demand for drugs, driving the treatment of this cancer.

The market in the Middle East & Africa and Latin America is likely to grow at a slower pace. The increase in the geriatric population and the increase in prevalence of the condition are accelerating the market growth in the region.

• For instance, in 2020, according to GLOBOCAN, 13,307 new cases of pancreatic cancer were reported in Brazil.

List of Key Companies in Pancreatic Cancer Treatment Market

Strong Focus on Collaborations by Key Players to Strengthen their Market Position

In terms of the competitive landscape, majority of the global market share is held by AstraZeneca, Pfizer Inc., and Novartis AG. These companies are the leading players offering innovative drugs. The major factors responsible for the leading position in the market are the regulatory approval for new products, product launches, mergers, and acquisition of the competitive players. Additionally, PharmaCyte Biotech, Inc. and Clovis Oncology are also some of the key players operating in the market. Moreover, an increase in investment in the development of advanced products has enabled AstraZeneca to hold a leading position in the market.

• For instance, in January 2022, AstraZeneca collaborated with Scorpion Therapeutics to discover, develop, and commercialize precision medicines against previously hard-to-target cancer proteins.

Moreover, Novartis AG is also focused on establishing collaborations and agreements with other players to bolster its presence across other countries.

• For instance, in December 2021, the company strengthened its immunotherapy pipeline by entering into a collaboration and licensing agreement with BeiGene for TIGIT inhibitor ociperlimab. The company gained the right to develop and commercialize ociperlimab in the U.S., Canada, and other countries through this agreement.

LIST OF KEY COMPANIES PROFILED:

• AstraZeneca (U.K.)


• Novartis AG (Switzerland)


• Pfizer Inc. (U.S.)


• Genentech (F. Hoffmann-La Roche Ltd) (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Ipsen Pharma (France)


• Oncolytics Biotech, Inc. (Canada)


• TME Pharma (Germany)


• Erytech Pharma (France)


• Clovis Oncology, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• February 2024 – The fast-track designation was granted for IMM-1-104 by the U.S. FDA for the treatment of pancreatic cancer.


• January 2022 – Novartis AG received an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It combines with other chemotherapy drugs to treat pancreatic cancer and other tumors.


• September 2021 – F. Hoffmann-La Roche Ltd partnered with NovoCure to develop Tumor Treating Fields (TTFields) in combination with anti-PD-L1 therapy, atezolizumab, for patients diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC).


• December 2020 – Bristol-Myers Squibb Company announced positive results from the phase III clinical trial, CheckMate – 548. The trial evaluated the efficacy of Opdivo in patients with newly diagnosed glioblastoma multiforme.


• June 2020 – Ipsen pharma received fast-track designation by the U.S. Food and Drugs Administration (FDA) for the use of the liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin known as NALIRIFOX for the treatment of patients suffering from locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC).


• December 2019 – AstraZeneca and Merck & Co. Inc., in collaboration, received the U.S. FDA approval for Lynparza (olaparib) for its use in the U.S. for the maintenance treatment of patients suffering from pancreatic cancer.

REPORT COVERAGE

An Infographic Representation of Pancreatic Cancer Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, type, treatment type, and end-user. Besides this, the market analysis highlights key industry developments and insights into market trends.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation